Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873358 | 0.92 | MEN1 (0.47) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL2873468 | 0.87 | ESR1 (0.43) | ESR1MAPTMEN1KMT2ALMNA | |
| SCHEMBL2872281 | 0.86 | ESR1 (0.44) | ESR1MAPTMEN1KMT2ALMNA | |
| SCHEMBL2878341 | 0.86 | ALDH1A1 (0.47) | ESR1MEN1KMT2AALDH1A1 | |
| SCHEMBL2869095 | 0.84 | MEN1 (0.50) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL2878396 | 0.81 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1 | |
| SCHEMBL2873169 | 0.79 | ACLY (0.51) | MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2878353 | 0.78 | MEN1 (0.47) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL2875356 | 0.77 | KMT2A (0.50) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL2873354 | 0.75 | ALDH1A1 (0.52) | MAPTLMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066628-B1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI AVENTIS (FR) | 2010-10-20 | — | — | EP | disclosed |
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, CYSLTR2 | ESR1 1686/4885MAPT 2271/4885MEN1 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.